Zanolimumab

• CAT Number: I042441
• CAS Number: 652153-01-0
• Purity: ≥95%

Zanolimumab (Cat No.: I042441) is a human monoclonal antibody targeting CD4, a glycoprotein found on the surface of immune cells such as helper T cells. It was developed for the treatment of T-cell malignancies, including cutaneous T-cell lymphoma (CTCL), and autoimmune diseases by modulating immune responses. By binding to CD4, zanolimumab aims to reduce pathogenic T-cell activity without broadly suppressing the immune system. Although it showed some promise in clinical trials, development was eventually discontinued due to limited efficacy and strategic considerations.

Reference

[1]. Rider DA, et al. A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity. Cancer Res. 2007 Oct 15;67(20):9945-53.
[Content Brief]